Biostage, Inc.
BSTG · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 0.15 | -0.22 | -0.08 |
| FCF Yield | -8.31% | -13.08% | -8.19% | -11.36% |
| EV / EBITDA | -6.89 | 0.00 | -10.05 | -2.48 |
| Quality | ||||
| ROIC | -231.97% | 0.00% | -1,099.33% | 632.83% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.63 | 0.78 | 0.84 | 0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 30.19% | -35.98% | -94.48% | 35.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 0.00 | 0.18 | 0.12 |
| Interest Coverage | 214.63 | 649.50 | -61.53 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.38 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -502.89 | 0.00 | 0.00 | 0.00 |